Slaughter and May advised DiaSorin S.p.A., a global leader in the laboratory diagnostics market, specializing in immunodiagnostics and molecular diagnostics, on the issuance of EUR 500 million senior unsecured equity-linked bonds due 2028 (the Bonds).
The proceeds of the issue of the Bonds will be used to partially finance the acquisition of Luminex Corporation (see 14 April briefing), including by way of partially or fully cancelling or repaying bridge and term loan facilities used to finance the acquisition, and for general corporate purposes. The Bonds will become convertible into ordinary shares of DiaSorin, subject to the approval of a resolution for a capital increase excluding shareholder pre-emption rights.
Application is intended to be made for the Bonds to be admitted to trading on the Vienna MTF operated by the Vienna Stock Exchange after the Issue Date.
Citigroup Global Markets Limited acted as the Sole Global Coordinator for the Offering, while BNP Paribas, Mediobanca – Banca di Credito Finanziario S.p.A., Unicredit Bank AG and Citigroup Global Markets Limited acted as Joint Bookrunners for the Offering.
Slaughter and May worked alongside DiaSorin’s Italian legal advisors, Pedersoli Studio Legale.